Markers of inflammation: data from the MOSAIC randomised trial of CPAP for minimally symptomatic OSA

ABSTRACT The Multi-centre Obstructive Sleep Apnoea Interventional Cardiovascular (MOSAIC) trial compared 6 months of CPAP therapy, versus no CPAP, in 391 patients with minimally symptomatic obstructive sleep apnoea (OSA). We now report some exploratory outcomes, markers of systemic inflammation (interleukin 6 (IL-6), IL-10, C reactive protein, tumour necrosis factor). We found no consistent changes (all p values >0.13).

Trial registration number: ISRCTN 34164388.

INTRODUCTION Intermittent hypoxia may generate free oxygen radicals and oxidative stress, activate expression of adhesion molecules and proinflammatory cytokines, and in turn damage the vascular endothelium with chronic low grade inflammation, ultimately leading to atheroma formation and vascular events. There are very few randomised controlled treatment trials in patients with OSA, and a recent meta-analysis relied exclusively on uncontrolled and non-randomised trials for its conclusion that there were small reductions in some markers of inflammation following CPAP. The MOSAIC randomised controlled trial looked at the effects of 6 months CPAP in 391 patients with minimally symptomatic OSA. We have now analysed stored plasma for markers of systemic inflammation, from MOSAIC patients with sufficient samples remaining, recruited at the Oxford, Reading and Taunton centres (303 patients).

METHODS Details of the MOSAIC study have been published previously. The online repository for this current research letter contains details of the main entry criteria, statistical analysis and analyses performed on the blood samples: interleukin 6 (IL-6), IL-10 (anti-inflammatory), highly sensitive C reactive protein (CRP) and tumour necrosis factor. Patients with CRP values over 8 mg/L, at baseline or 6 months, were discarded from each analysis as they were assumed to represent significant intercurrent infection. As in the primary outcomes paper, the analysis was on an intention-to-treat basis, but with secondary analyses to explore the effect of CPAP compliance, as this was low overall (median 2.39, IQR 0.36 to 4.59, hour:min/night).

RESULTS Patient characteristics, pre and post levels of oxygen desaturation index (ODI), and compliance data are in the original paper. Table 1 shows the results of the blood assays. There were no consistent changes in any of the outcomes, with all p values >0.13, and no differences were seen when comparing high and low CPAP compliers (online data supplement). Sensitivity analyses using all subjects, regardless of whether the CRP was >8 mg/l or not, were no different (data not shown).

DISCUSSION We have shown no changes in a limited set of inflammatory markers following 6 months of CPAP therapy versus untreated controls, in patients with mild-to-moderate OSA from the MOSAIC trial. This is despite there being a clear improvement in sleepiness, and an improvement in endothelial function (albeit in a subset of patients). Low CPAP compliance is unlikely to be the explanation for these negative findings, given that there was no suggestion of an effect even in the higher CPAP compliers (>24 h/night). Our results are in agreement with our earlier 1 month randomised controlled trial in a more severe group of patients with OSA. It is also in agreement with a recently published randomised controlled trial which showed no effect of 24 weeks CPAP on highly sensitive CRP in obese patients with moderate-to-severe OSA, despite a small fall in systolic blood pressure. The small effect on CRP IL-6 and tumour necrosis factor seen in some uncontrolled trials is likely to be the result of regression to the mean. Reductions in catecholamine levels seem a more likely explanation for the improved endothelial function.

Table 1 Baseline, 6 month, mean change and treatment effect data for all outcomes (excluding patients with CRP values >8 at baseline or follow-up)

<table>
<thead>
<tr>
<th>Analysis</th>
<th>CRP</th>
<th>Interleukin 6</th>
<th>Interleukin 10</th>
<th>Tumour necrosis factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>N Baseline (SD)</td>
<td>113 (0.84–3.48)</td>
<td>1.66 (0.87–3.44)</td>
<td>+0.03 (1.78)</td>
<td>+0.03 (1.78)</td>
</tr>
<tr>
<td>Time course (SD)</td>
<td>125 (0.84–3.32)</td>
<td>1.49 (0.82–2.75)</td>
<td>−0.19 (1.56)</td>
<td>−0.19 (1.56)</td>
</tr>
<tr>
<td>Treatment effect (95% CI)</td>
<td>0.30</td>
<td>0.62</td>
<td>0.14</td>
<td>0.37</td>
</tr>
</tbody>
</table>

Baseline and 6 month values are summarised by median (25th–75th centiles). CRP, C reactive protein.

J R Stradling, 1 S E Craig, 1 M Kohler, 1, 2 D Nicoll, 1 L Ayers, 3 A J Nunn, 4 D J Bratton 4

1 Oxford Centre for Respiratory Medicine and Oxford Biomedical Research Centre, Churchill Hospital Campus, Oxford University Hospitals NHS Trust, Oxford, UK
2 Sleep Disorders Centre and Pulmonary Division, University Hospital of Zurich, Zurich, Switzerland
3 Department of Clinical Immunology, Churchill Hospital Campus, Oxford University Hospitals NHS Trust, Oxford, UK
4 MRC Clinical Trials Unit at UCL, Aviation House, London, UK

Correspondence to Professor John R Stradling, Oxford Centre for Respiratory Medicine and Oxford Biomedical Research Centre, Churchill Hospital Campus, Oxford University, Oxford OX3 7LJ, UK; john.stradling@orh.nhs.uk

Competing interests None.

Patient consent Obtained.

Ethics approval COREC No: 05/Q1604/159.

Provenance and peer review Not commissioned; externally peer reviewed.
Research letter

Data sharing statement All data in this article are freely available on request.

▸ Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/thoraxjnl-2014-205958).


Received 27 June 2014
Revised 15 August 2014
Accepted 18 August 2014
Published Online First 2 September 2014
doi:10.1136/thoraxjnl-2014-205958

REFERENCES
Correction


The results for tumour necrosis factor (TNF) as shown in Table 1 are incorrect and in fact correspond to the results for CRP. The correct results for TNF are shown below:

<table>
<thead>
<tr>
<th></th>
<th>Standard Care</th>
<th>CPAP</th>
<th></th>
<th></th>
<th></th>
<th>Treatment effect</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Baseline</td>
<td>6 Months</td>
<td>Mean change (SD)</td>
<td>N</td>
<td>Baseline</td>
<td>6 Months</td>
</tr>
<tr>
<td>Highly sensitive CRP (mg/L)</td>
<td>113</td>
<td>1.56 (0.84–3.48)</td>
<td>1.66 (0.87–3.44)</td>
<td>0.03 (1.78)</td>
<td>125</td>
<td>1.86 (0.84–3.32)</td>
<td>1.49 (0.82–2.75)</td>
</tr>
<tr>
<td>Interleukin 6 (pg/mL)</td>
<td>111</td>
<td>0.48 (0.19–0.92)</td>
<td>0.58 (0.26–1.09)</td>
<td>0.14 (0.61)</td>
<td>125</td>
<td>0.44 (0.24–0.79)</td>
<td>0.52 (0.22–0.96)</td>
</tr>
<tr>
<td>Interleukin 10 (pg/mL)</td>
<td>111</td>
<td>0.59 (0.33–1.02)</td>
<td>0.70 (0.39–1.21)</td>
<td>0.11 (1.22)</td>
<td>125</td>
<td>0.61 (0.29–1.01)</td>
<td>0.60 (0.33–1.04)</td>
</tr>
<tr>
<td>Tumour necrosis factor (pg/mL)</td>
<td>111</td>
<td>0.96 (0.45–1.35)</td>
<td>1.07 (0.48–1.48)</td>
<td>0.10 (0.40)</td>
<td>125</td>
<td>1.01 (0.45–1.35)</td>
<td>1.17 (0.61–1.56)</td>
</tr>
</tbody>
</table>

Table 1 Baseline, 6 month, mean change and treatment effect data for all outcomes (excluding patients with CRP values >8 at baseline or follow-up)

Thorax 2015;70:319. doi:10.1136/thoraxjnl-2014-205958corr1